Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Daridorexant (Primary) ; Suvorexant; Zolpidem
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 18 Sep 2019 Status changed from recruiting to completed.
- 19 Mar 2019 Planned End Date changed from 1 Feb 2019 to 31 Jul 2019.
- 19 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 31 Jul 2019.